IV Chemotherapy (Regimen 1)

DRUG2 trials

Sponsors

Amgen, UNICANCER

Conditions

Advanced Solid TumorsColorectal Adenocarcinoma Metastatic in the LiverColorectal CancerKirsten Rat Sarcoma (KRAS) pG12C Mutation

Phase 1

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Active, not recruitingNCT04185883

AmgenAdvanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation

Start: 2019-12-17End: 2027-12-05Updated: 2025-10-22

Phase 3

Liver-directed Chemotherapy After Surgery of Liver Metastases of Colorectal Cancer in Patients With High Risk of Recurrence of Their Disease

Not yet recruitingNCT07284394

UNICANCERColorectal Adenocarcinoma Metastatic in the Liver, Colorectal Cancer

Start: 2026-03-31End: 2034-09-30Target: 272Updated: 2025-12-16

Related Papers

Abstract 2929: Immune and pharmacodynamic effects of sotorasib plus panitumumab in <i>KRAS</i> G12C-mutant colorectal cancer: Paired biopsy results from CodeBreaK 101.

Cancer Research2026-04-03

Long-term safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated <i>KRAS</i> G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 (phase 1b).

Journal of Clinical Oncology2025-05-284 citations

A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with <i>KRAS</i> G12C–mutated metastatic colorectal cancer (CodeBreaK 301).

Journal of Clinical Oncology2025-01-272 citations

Pooled safety analysis and management of sotorasib-related adverse events in <i>KRAS</i> G12C-mutated advanced non-small cell lung cancer

The Oncologist2025-01-012 citations

Sotorasib plus carboplatin and pemetrexed in <i>KRAS</i> G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial.

Journal of Clinical Oncology2024-06-0115 citations

Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with <i>KRAS</i>G12C mutation: A phase 1b study.

Journal of Clinical Oncology2024-06-011 citations

A phase 1b study of sotorasib combined with panitumumab as second-line treatment of <i>KRAS</i> G12C<i>-</i>mutated colorectal cancer.

Journal of Clinical Oncology2024-01-203 citations

Sotorasib with panitumumab in chemotherapy-refractory KRAS<sup>G12C</sup>-mutated colorectal cancer: a phase 1b trial.

2024-01-0465 citations

Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated <i>KRAS </i>G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy.

Journal of Clinical Oncology2023-06-0118 citations

A phase 1b study of sotorasib, a specific and irreversible KRAS<sup>G12C </sup>inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101).

Journal of Clinical Oncology2022-01-1914 citations

Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRAS<sup>G12C</sup> inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101).

Journal of Clinical Oncology2021-05-2010 citations

Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRAS<sup>G12C</sup> inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring <i>KRAS</i> p.G12C mutation (CodeBreak 101).

Journal of Clinical Oncology2020-05-209 citations